Daily Archives: September 15, 2021

Singapore-Based Global Schools Foundation Announces Strategic Partnership With Dwight School Seoul

GSF Certificate of recognition

SINGAPORE, Sept. 15, 2021 (GLOBE NEWSWIRE) — Singapore-based Global Schools Foundation has announced that it has entered into a strategic partnership with Dwight School Seoul, one of South Korea’s top international schools, popular with expatriates and locals.

Dwight School Seoul is the first International Baccalaureate (IB) World School in Seoul with authorisation in all three IB Programmes for students aged 3-18 years. The Seoul campus spreads across 200,000 sq. feet, with facilities that kindle student interest in innovative pursuits to make them inquisitive, informed, self-aware and ethical citizens.

GSF, founded and headquartered in Singapore, is a not-for-profit entity focussed on the K12 education sector. It owns and operates a network of 23 premium international schools across eight countries, which offer multiple curricula from IB to Cambridge IGCSE, through a data-driven, technology-intensive approach.

In 2021, GSF was recognised as the “World’s Most Awarded Network of Schools” by World Book of Records, UK & Switzerland, for being a recipient of 235 awards in different categories from Innovation to Sustainability.

The partnership between GSF and Dwight School (Seoul) marks GSF’s entry into South Korea’s K12 market, which will help expand its reach and ideology. In return, Dwight School can expect to benefit from the synergies, learning technologies and innovation capabilities of GSF.

Welcoming the partnership, GSF Chairman Mr Atul Temurnikar said: “We are delighted to work with Dwight leadership to support their vision of high academic standards to students. In the next few years, we plan to establish a second K12 campus in South Korea, as well as expand across North Asia and South-East Asia.”

Dwight’s Head of School for Seoul, Mr Jason Hayter, said the team was thrilled to partner with GSF. “This partnership will help build our ideology of igniting the spark of genius in every child. We look forward to working closely with GSF to strengthen our capabilities in preparing our students for the 21st century.”

GSF’s entity, Global Schools Holdings, is part of the Scale Up SG Programme by Enterprise Singapore (ESG), which focuses on the growth of home-grown, high-potential entities and helps them increase their global reach to become leaders in their field. GSH was among the 25 handpicked organisations to be included in the pioneer batch of the Scale Up programme.

About GSF

Founded in 2002, Global Schools Foundation is a community-oriented institution whose mission is to nurture young minds into global leaders of the future. Students of GSF schools have been recipients of several top accolades in IB & Cambridge curricula.

About Dwight School Seoul 

Specially selected by the Seoul Municipal Government to open a model IB World School in Seoul, Dwight’s global network spans across five global campuses in New York, London, Dubai, Shanghai and Seoul. Its goal is to create world leaders through academic excellence and develop student passion through an individualised, strategic approach.

Media Contact:
Ms Rupali Karekar

Related Images

Image 1: GSF Certificate of recognition

The Certificate by World Book of Records

This content was issued through the press release distribution service at Newswire.com.



Degreed adds embedded skills and learning analytics through strategic partnership with Visier

Deal will provide advanced analytics on skill data so Degreed clients can plan learning and development strategies to support evolving and transformative business priorities

PLEASANTON, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Workforce upskilling platform Degreed announced a strategic partnership with Visier, the globally recognized leader in people analytics and planning, to deliver business-relevant insights around workforce skills and future skill needs. Visier’s analytics engine will be embedded in a new, optional offering inside Degreed’s learning experience platform and is planned for general availability in Q4 of this year.

Skill data is essential to managing digital transformation and staying ahead with competitive innovation. Companies that quantify the gap between skills they have and those they need are 1.7x more likely to succeed in transformations. But a lack of insight into workforce skills is hindering over half (53 percent) of workforce transformations. One big reason why: over 45 percent of talent leaders feel they lack the technology to assess and track their workforce skills.

Degreed and Visier are collaborating to provide a simple and intuitive solution inside the user-friendly Degreed experience that helps L&D teams and their stakeholders understand and visualize the skills and capabilities inside organizations so they can make data-backed decisions about their upskilling initiatives.

Rob Wellington, Director of Experience Partnerships at Degreed, said, “Having timely data on workforce skills is vital for every organization today. Without it, learning, talent and HR leaders are working blind. Degreed’s partnership with Visier will bring much-needed clarity on skill data, making it actionable and ensuring that businesses have the skills and learning where they need them most.”

“This partnership is an exciting opportunity for Degreed customers to get actionable insights into business-critical skills,” said Dave Weisbeck, Chief Strategy Officer at Visier. “Our combined forces pair together learning experience data, skills data and Visier’s robust analytics engine. With Degreed, customers will have a real-time and complete picture of what skills are in demand, where skills exist in an organization and what skill development to prioritize to meet coming business needs.”

If you would like to learn more about the partnership and how advanced skills insights can help you make your learning and development programs more impactful, visit our landing page to talk with a Visier + Degreed expert.

About Degreed

Degreed is the workforce upskilling platform for one in three Fortune 50 companies. We connect all your learning, talent development, and internal mobility opportunities to intelligence on the skills your business needs next. And we do it all in one easy, fluid, skill-building experience powered by your people’s expertise and interests. So you can transform your workforce from within. Founded in 2012, Degreed is headquartered in Pleasanton, California, with additional offices in Salt Lake City, New York, London, Amsterdam, and Brisbane.

Learn more about Degreed: Website | YouTube | LinkedIn | Twitter

About Visier

Visier is the recognized global leader in people analytics and workforce planning. Founded in 2010 by the pioneers of business intelligence, Visier focuses on what matters to business leaders: answering the right questions, even the ones a person might not know to ask. Questions that shape business strategy, provide the impetus for taking action, and drive better business outcomes through workforce optimization. Headquartered in Vancouver, BC with offices and team members worldwide, Visier has 11,000 customers in 75 countries around the world, including enterprises like Adobe, BASF, Bridgestone, Electronic Arts, McKesson, Merck KGaA, Uber and more.

For more information, visit www.visier.com.

Media contacts:

Sarah Danzl, Head of Global Communications at Degreed | sarah@degreed.com, +1.303.817.7137

WillScot Mobile Mini Announces Closing Of Third Secondary Offering Which Completes Full Sponsor Exit

PHOENIX, Sept. 15, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a North American leader in modular space and portable storage solutions, today announced the closing of the previously announced underwritten secondary offering (the “Offering”) of 21,410,019 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Shares were offered by Sapphire Holding S.à r.l., an entity controlled by TDR Capital (the “Selling Stockholder”), at a price to the public of $28.50 per share. The Company did not offer any shares of Common Stock in the Offering and did not receive any of the proceeds from the Offering. In addition, the Company repurchased 2,379,839 shares of Common Stock directly from the Selling Stockholder (the “Share Repurchase”). The price per share paid by the Company was equal to the price per Share paid by the underwriters for the Shares in the Offering. The aggregate 23,789,858 shares of Common Stock represented the entirety of TDR Capital’s remaining position in the Company. In accordance with the terms of the shareholder agreement, Stephen Robertson also resigned from the Company’s Board of Directors. As of today, following the close of the transaction, the Company has 223,993,904 shares of Common Stock outstanding, and nearly 100% of the Company’s Common Stock is now held by non-affiliates.

Brad Soultz, Chief Executive Officer, commented, “As this third secondary offering closes, I am grateful to TDR for over a decade of support for our legacy WillScot business. In particular, thank you to both Steve Robertson and Gary Lindsay for their invaluable service on the WillScot Mobile Mini Board of Directors. As we continue to extend our impressive trajectory of growth and associated stakeholder value creation, the talent that we are attracting to WillScot Mobile Mini, across all levels of our organization, is unprecedented. The departure of Steve and Gary creates an opportunity to further diversify our Board with directors of the highest caliber with the skills and perspectives that support and enhance our strategy.”

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Any forward-looking statement speaks only at the date which it is made, and WillScot Mobile Mini disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Mobile Mini Holdings Corp.

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 275 branch locations and additional drop lots throughout the United States, Canada, Mexico, and the United Kingdom.

Contact Information

Investor Inquiries:

Nick Girardi


Media Inquiries:

Scott Junk


Zoom Unveils Reseller Partner Program for Zoom Phone BYOC

Zoom Phone Bring Your Own Carrier (BYOC) Offers New Revenue Opportunity to Resellers and Maximum Flexibility to Customers

Zoom Phone Provider Exchange Connects Customers Directly with Providers

Zoom Phone Reaches New Milestone with 2 Million Seats Sold

SAN JOSE, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today at Zoomtopia Partner Connect announced that its reseller partners will have the opportunity to sell Zoom Phone Bring Your Own Carrier (BYOC) licenses. They will also be able to connect customers who use enhanced cloud peering to access PSTN to Zoom Phone Provider Exchange, a new way to discover providers and follow a self-service journey to provision phone numbers securely. Zoom is currently running a pilot program for select resellers that meet the requirements to sell Zoom Phone BYOC and expects to welcome a wider pool of resellers by the end of the year.

Built on Zoom’s intuitive platform, Zoom Phone is a full-featured cloud phone system for businesses of all sizes. Zoom Phone BYOC provides enterprise customers with the flexibility to keep their current PSTN service providers by redirecting existing voice circuits to the Zoom Phone cloud, or implement a hybrid solution with Zoom Calling Plans. This high-value capability allows customers to enjoy all of the benefits of Zoom Phone while keeping their existing service provider contracts, phone numbers, and calling rates with their preferred carrier of record.

Previously, only Zoom Master Agents had the opportunity to refer deals for Zoom Phone and Zoom Phone BYOC. Now Zoom’s reseller partners from around the world who meet the requirements and qualify will be authorized to resell Zoom Phone BYOC.

Zoom Phone BYOC customers who use enhanced cloud peering to connect to PSTN will also soon be able to access Zoom Phone Provider Exchange. The new Zoom Phone Provider Exchange offers a streamlined experience for Zoom Phone BYOC customers to select the provider of their choice, and provision phone numbers directly in the Zoom portal. As a result, Zoom Phone BYOC customers will have more choice and flexibility in terms of providers and their geographic reach.

“As our channel program continues to evolve, I’m excited to introduce the Reseller Program for Zoom Phone BYOC as a new opportunity for our reseller partners,” said Laura Padilla, Head of Global BD and Channel. “We’ve seen a lot of success in selling Zoom Phone, reaching two million seats in just 10 quarters, and I see a lot of opportunity for our resellers with our Zoom Phone BYOC program. Zoom Phone BYOC provides customers with the flexibility to stay on their current carrier or easily use a combination to best meet their geographic reach and service needs.”

To learn more about becoming a Zoom Partner, please visit https://partner.zoom.us or reach out to partner-success@zoom.us.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Zoom Public Relations
Matt Nagel
Public Relations

Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine

Toripalimab plus standard chemotherapy demonstrates improvement in PFS in first-line advanced nasopharyngeal carcinoma

SHANGHAI and REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced publication of a cover article in the September issue of Nature Medicine featuring clinical data from the pivotal study “JUPITER-02”, a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC).

Titled Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial, the paper highlights that the addition of toripalimab to standard of care gemcitabine-cisplatin (GP) chemotherapy as a first-line treatment for patients with recurrent or metastatic NPC provided superior progression free survival (PFS) compared to GP alone [median PFS of 11.7 vs 8.0 months, hazard ratio (HR) = 0.52 (95% confidence interval (CI): 0.36–0.74), P = 0.0003], and with a manageable safety profile. The impact of the addition of toripalimab on PFS was demonstrated in patients regardless of PD-L1 expression status. Although overall survival data were not yet mature, as of February 18, 2021, a 40% reduction in risk of death was observed in the toripalimab arm compared to the placebo arm (HR = 0.603 (95% CI: 0.364–0.997)). The incidence of grade ≥3 treatment emergent adverse events (TEAEs) (89.0% vs 89.5%), TEAEs leading to discontinuation of toripalimab/placebo (7.5% vs 4.9%), and fatal TEAEs (2.7% vs 2.8%) was similar between both arms. Immune-related adverse events (irAEs) (39.7% vs. 18.9%) and Grade ≥3 irAEs (7.5% vs. 0.7%) were more frequent in the toripalimab arm. The full results can be found in the on-line edition of Nature Medicine.

“There are currently no PD-1 blocking antibodies approved for NPC in the United States. We are pleased that this study has been selected for cover article publication in this highly-respected journal,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “This is a strong signal that further validates the potential advance that toripalimab in combination with chemotherapy would represent as a new standard-of-care first-line therapy for patients with advanced NPC, an aggressive and difficult-to-treat cancer.”

A biologics license application has been submitted to the U.S. Food and Drug Administration (“FDA”) for toripalimab in combination with gemcitabine and cisplatin for first-line treatment for patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for second-line or above treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.

About JUPITER-02
The JUPITER-02 Study (ClinicalTrials.gov identifier: NCT03581786) is a randomized, double-blind, placebo-controlled, international multi-center Phase 3 clinical trial comparing the efficacy and safety of toripalimab versus placebo in combination with Gemcitabine/Cisplatin, as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma. Professor Ruihua Xu from Sun Yat-sen University Cancer Centre is the lead principal investigator of the study. The largest Phase 3 clinical trial to date evaluating a checkpoint inhibitor plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, JUPITER-02 was conducted in mainland China, Taiwan and Singapore and enrolled a total of 289 patients.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system’s ability to attack and kill tumor cells. More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States. Ongoing or completed pivotal clinical trials are evaluating the safety and efficacy of toripalimab for a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). On December 17, 2018, toripalimab was granted a conditional approval by the National Medical Products Administration (NMPA) for the second-line treatment of unresectable or metastatic melanoma. In December 2020, toripalimab was successfully included in the updated National Reimbursement Drug List. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy. In April 2021, NMPA granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. In addition, two supplemental NDAs for toripalimab in combination with chemotherapy for the first-line treatment of patients with advanced, recurrent or metastatic NPC or for the first-line treatment of patients with advanced, or metastatic esophageal squamous cell carcinoma were accepted by the NMPA for review in February and July 2021 respectively.

In the United States, the first toripalimab BLA has been submitted to the FDA for the treatment of recurrent or metastatic NPC. The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the 1st line treatment of recurrent or metastatic NPC and for toripalimab monotherapy in the 2nd line and subsequent treatment of recurrent or metastatic NPC. There are currently no PD-1 blocking antibodies approved for use in NPC in the United States. Additionally, FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and orphan drug designation for NPC, mucosal melanoma and soft tissue sarcoma. Earlier in 2021 Coherus in-licensed rights to develop and commercialize toripalimab in the United States and Canada. Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple rare cancers and highly prevalent cancers.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 44 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for an anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first fully human neutralizing monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in more than 12 countries and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. For additional information, please visit www.coherus.com.

Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch toripalimab, an anti-PD-1 antibody, as well as biosimilars of Lucentis®, Humira®, and Avastin®, if approved.

UDENYCA® is a trademark of Coherus BioSciences, Inc.

Avastin® and Lucentis® are registered trademarks of Genentech, Inc.

Humira® is a registered trademark of AbbVie Inc.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ ability to generate cash flow from its UDENYCA® business; Coherus’ and Junshi Biosciences’ ability to co-develop toripalimab, and Coherus’ ability to commercialize toripalimab, or any other drug candidates developed as part of its collaboration with Junshi Biosciences in the licensed territory; Coherus’ ability to expand a late-stage pipeline into the rapidly growing checkpoint inhibitor market; any market size expectation for checkpoint inhibitor therapeutic agents in the United States; the potential for toripalimab to gain approval in the United States for nasopharyngeal carcinoma or any indication; Coherus’ and Junshi Biosciences’ plans to file additional toripalimab BLAs with the FDA over the next three years for other clinical indications; Coherus’ plans to invest the cash generated by its biosimilar commercial business to build a focused immuno-oncology franchise; Coherus’ ability to prepare for projected launches through 2023 of biosimilars of Humira®, Avastin® and Lucentis®, if approved.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; the risks and uncertainties of the regulatory approval process, including the timing of Coherus’ regulatory filings; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ drug candidates; and the risks and uncertainties of possible patent litigation. All forward-looking statements contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 25, 2021,its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2021, filed with the Securities and Exchange Commission on August 5, 2021 and its future periodic reports to be filed with the Securities and Exchange Commission. Results for the quarter ended June 30, 2021 are not necessarily indicative of our operating results for any future periods.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
+ 86 021-2250 0300

Solebury Trout
Bob Ai
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
+ 86 021-6105 8800

Coherus Contact Information:
IR Contact:
McDavid Stilwell
Coherus BioSciences, Inc.
+1 (650) 395-0152

Media Contact:
Sheryl Seapy
Real Chemistry
+1 (949) 903-4750

UPDATE – Good Things are Worth the Wait: Heineken Teams Up With Daniel Craig to Celebrate Release of No Time To Die

Heineken ‘Worth the Wait’

Heineken® today reveals a new commercial concept in collaboration with Daniel Craig called ‘Worth The Wait’, which celebrates the highly anticipated release of the new James Bond film No Time To Die. The advert shows Daniel Craig waiting patiently for the first satisfying sip of an ice-cold Heineken® beer, an ode to fans who have eagerly awaited the next installment of the franchise and showing that the best things come to those who wait.

  • Heineken® has collaborated with actor Daniel Craig to create the‘Worth The Wait’ commercial.

LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) — Heineken® today reveals a new commercial concepted in collaboration with Daniel Craig called ‘Worth The Wait’, which celebrates the highly anticipated release of the new James Bond film No Time To Die. The advert shows Daniel Craig waiting patiently for the first satisfying sip of an ice-cold Heineken® beer, an ode to fans who have eagerly awaited the next installment of the franchise and showing that the best things come to those who wait.

The Worth the Wait film is available here.

No Time To Die will be released internationally in cinemas from September 30 2021 through Universal Pictures International and in the U.S. on October 8 from Metro Goldwyn-Mayer (MGM) via their United Artist Releasing banner.

Bram Westenbrink, Global Head Heineken® Brand, said:Heineken® has been a proud partner of James Bond films since 1997. So, like all Bond fans, we also can’t wait for No Time To Die to hit cinemas. That said, we believe some things really are worth waiting for. And now we can prove it. Whether it’s an ice-cold Heineken® or an action-packed Blockbuster – the best things truly do come to those who wait.”

Testing the truth behind the sentiment, Heineken® carried out a real-world social experiment to prove that good things are indeed worth the wait. In the experiment, 115 people were given cold Heineken® or Heineken® 0.0 beer at intervals between 0-30 minutes, showing that people who waited 20 minutes had the highest levels of satisfaction.

Editorial Information:

Press Enquiries: HNKNbond@edelman.com

  • Worth the Wait video is here
  • Images are here

Advertising Credits:

Global Chief Creative Officer Publicis WW: Bruno Bertelli
Chief Creative Officer: Cristiana Boccassini
International Coordination Creative Director: Guy Lewis
Copywriter: Olga Alonso
Art Director: Alexia Vindret
Chief Creation Officer: Francesca Zazzera
Account Director: Francesca Baldrighi

Production Company: Smuggler
Director: Sam Gold
Eps: Patrick Milling-Smith & Alison Kunzman
Producer: Erin Wile
DP: Darren Lew
PD: Pete Zumba
Post Producer: Filip Ilic
Colorist: Tim Masick @ Co.3
Color Producer: Kevin Breheny
Editor: Guido Notari

Experiment Findings:

Key findings included:

  • Participants who waited 20 minutes showed the highest satisfaction levels with their beer (41%)
  • Participants who waited 30 minutes had the highest satisfaction scores with the taste of the beer (31%)
  • 4 in 10 participants attribute the anticipation of receiving their beer to their satisfaction.
  • More than half of the participants (56%) agree that they enjoy things more when they have to wait for them a little.
  • If participants could choose, they feel that a 6.4-minute wait would be the optimal time to have waited for their beer. However, our research found that satisfaction peaked in the 20 minutes wait group. Implying that instant, or at least quicker gratification, is not as satisfying as people might think

Daria A Bakina, PhD, Social Psychologist and Research Director at Edelman Data & Intelligence, said: “This research follows a long tradition of conducting experiments in the “real world”, under real circumstances, within the field of social psychology. The findings of this study show that waiting may not be a bad thing – in fact, there’s more enjoyment after needing to overcome an obstacle like a 20 minute wait for a refreshing “Perfect Pour.”

Further information on research findings is available on request.


HEINEKEN is the world’s most international brewer. It is the leading developer and marketer of premium beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 300 international, regional, local and specialty beers and ciders. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brewing a Better World”, sustainability is embedded in the business.

HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We employ over 85,000 employees and operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Heineken N.V. and Heineken Holding N.V. shares trade on the Euronext in Amsterdam. Prices for the ordinary shares may be accessed on Bloomberg under the symbols HEIA NA and HEIO NA and on Reuters under HEIN.AS and HEIO.AS. HEINEKEN has two sponsored level 1 American Depositary Receipt (ADR) programmes: Heineken N.V. (OTCQX: HEINY) and Heineken Holding N.V. (OTCQX: HKHHY).

Most recent information is available on HEINEKEN’s website: www.theHEINEKENcompany.com and follow us on Twitter via @HEINEKENCorp.

No Time To Die is the official title of the 25th James Bond adventure. The film — from Albert R. Broccoli’s EON Productions, Metro Goldwyn Mayer Studios (MGM), and Universal Pictures International — is directed by Cary Joji Fukunaga and stars Daniel Craig, who returns for his fifth film as Ian Fleming’s James Bond 007.

Written by Neal Purvis & Robert Wade (Spectre, Skyfall), Cary Joji Fukunaga, and Phoebe Waller- Bridge (Killing Eve, Fleabag), the film will be released globally from September 30 2021 through Universal Pictures International and on October 8 in the US through MGM via their United Artists Releasing banner.

In No Time To Die, Bond has left active service and is enjoying a tranquil life in Jamaica. His peace is short-lived when his old friend Felix Leiter from the CIA turns up asking for help. The mission to rescue a kidnapped scientist turns out to be far more treacherous than expected, leading Bond onto the trail of a mysterious villain armed with dangerous new technology.

ABOUT EON Productions
EON Productions Limited and Danjaq LLC are wholly owned and controlled by the Broccoli/Wilson family. Danjaq is the US based company that co-owns, with Metro Goldwyn Mayer Studios, the copyright in the existing James Bond films and controls the right to produce future James Bond films. EON Productions, an affiliate of Danjaq, is the UK based production company that has made the James Bond films since 1962 and together with Danjaq controls all worldwide merchandising. For more information, visit www.007.com.

Metro Goldwyn Mayer (MGM) is a leading entertainment company focused on the production and global distribution of film and television content across all platforms. The company owns one of the world’s deepest libraries of premium film and television content as well as the premium pay television network EPIX, which is available throughout the U.S. via cable, satellite, telco, and digital distributors. In addition, MGM has investments in numerous other television channels, digital platforms, interactive ventures, and is producing premium short-form content for distribution. For more information, visit www.mgm.com.

United Artists Releasing, a joint venture between Metro Goldwyn Mayer (MGM) and Annapurna Pictures (Annapurna), is a U.S. theatrical releasing company. Built upon the legacy of the iconic United Artists motion picture studio, the joint venture provides a home where filmmakers are supported by thoughtful approaches to marketing, publicity and distribution. United Artists Releasing offers content creators an alternative distribution option outside of the studio system and supports Annapurna and MGM’s film slates as well as the films of third-party filmmakers.

Universal Pictures International (UPI) is the international marketing and distribution division for Universal Pictures. In the United Kingdom, Ireland, Spain, Italy, Germany, Austria, Switzerland, the Netherlands, France, Russia, Korea, Australia, New Zealand, Mexico and China (including Hong Kong SAR), UPI directly markets and distributes movies through its own offices, creating local campaigns and release strategies. In other parts of the world, UPI partners with Warner Bros, with Paramount through United International Pictures (UIP), and with Sony, either directly or through UIP, to distribute its films. Universal Pictures is part of NBCUniversal, one of the world’s leading media and entertainment companies in the development, production, and marketing of entertainment, news, and information to a global audience. NBCUniversal is a subsidiary of Comcast Corporation.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0c389a2a-bede-4037-8b93-58520c843bf1

The photo is also available via AP PhotoExpress.

U.S. Polo Assn. to Support the 2021 Argentine Triple Crown Tournaments

U.S. Polo Assn.

U.S. Polo Assn.

WEST PALM BEACH, Fla. and BUENOS AIRES, Argentina, Sept. 15, 2021 (GLOBE NEWSWIRE) — U.S. Polo Assn., the official brand of the United States Polo Association (USPA), has announced a partnership with the Argentine Polo Association (AAP) and the 2021 Argentine Triple Crown Tournaments, which will include field banners, co-branded staff outfitting and global promotion of the event across various digital platforms.

The Triple Crown Tournaments are the most prestigious of any tournament series and include the Tortugas Country Club Open, Hurlingham Club Open and 128th HSBC Argentine Polo Open. The three-part series starts October 5 and will conclude on December 11 with the 128th HSBC Argentine Polo Open Finals. The top players in the world play annually in the Triple Crown, including Adolfo Cambiaso, Facundo Pieres and Hilario Ulloa. In addition, the Women’s Argentine Polo Open presented by Cremas Caviahue will be played during this timeframe, highlighting some of the best female polo players in the world.

“U.S. Polo Assn. is proud to partner with the Argentine Polo Association to support the 2021 Argentine Triple Crown, one of the most prestigious and important professional polo tournaments in the world,” said J. Michael Prince, President and CEO of USPA Global Licensing, which manages the global, multi-billion-dollar U.S. Polo Assn. brand. “Our partnership with the AAP is yet another way U.S. Polo Assn. stands out as an authentic, sport-inspired global brand by engaging sports fans and consumers in one of the greatest polo venues in the world.”

U.S. Polo Assn. now sponsors three of the most important tournaments in the world for the sport of polo: the U.S. Open Polo Championship, the British Gold Cup and the 128th HSBC Argentine Polo Open.

“It’s wonderful to have the support of U.S. Polo Assn., a brand that exudes authenticity and commitment to polo, for this most prominent Argentine event series,” said Lucas Adur, CEO of Argentine Polo Association. “The Argentine Polo Association puts forth and supports world-class events like this to further advance the sport, and we couldn’t do this without the support of U.S. Polo Assn. and our other outstanding partners.”

Global Polo TV (GPTV), the world’s leading production entity for global polo broadcasts and polo lifestyle content, has acquired exclusive rights to sell viewership of the 2021 Triple Crown in the United States and Canada. Learn more at globalpolo.com.

About U.S. Polo Assn. and USPA Global Licensing Inc. (USPAGL)

U.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the nonprofit governing body for the sport of polo in the United States and one of the oldest sports governing bodies, having been founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through some 1,100 U.S. Polo Assn. retail stores, department stores, sporting goods channels, independent retailers and e-commerce, U.S. Polo Assn. offers apparel for men, women and children, as well as accessories, footwear, travel and home goods in 180 countries worldwide. Recently ranked the fifth largest sports licensor in License Global magazine’s 2020 list of “Top 150 Global Licensors,” U.S. Polo Assn. is named alongside such iconic sports brands as the National Football League, the National Basketball Association and Major League Baseball. Visit uspoloassnglobal.com.

USPA Global Licensing Inc. (USPAGL) is the for-profit subsidiary of the USPA and its exclusive worldwide licensor. USPAGL manages the global, multi-billion-dollar U.S. Polo Assn. brand and is the steward of the USPA’s intellectual properties, providing the sport with a long-term source of revenue. Through its subsidiary, Global Polo Entertainment (GPE), USPAGL also manages Global Polo TV, the world’s leading production entity for global polo broadcasts and polo lifestyle content. Learn more at globalpolo.com.

For further information contact: 

Shannon Stilson – AVP, Marketing
Phone +001.561.227.6994 – Email: sstilson@uspagl.com

Stacey Kovalsky – Senior Director, Global Communications
Phone +001.561.790.8036 – Email: skovalsky@uspagl.com

Related Images

Image 1: U.S. Polo Assn.

U.S. Polo Assn.

This content was issued through the press release distribution service at Newswire.com.